Cargando…
Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach
BACKGROUND: Non–small-cell lung cancer (NSCLC) is a heterogeneous disease, with multiple different oncogenic mutations. Approximately 25–30% of NSCLC patients present KRAS mutations, which confer poor prognosis and high risk of tumor recurrence. About half of NSCLCs with activating KRAS lesions also...
Autores principales: | Caiola, Elisa, Falcetta, Francesca, Giordano, Silvia, Marabese, Mirko, Garassino, Marina C., Broggini, Massimo, Pastorelli, Roberta, Brunelli, Laura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280460/ https://www.ncbi.nlm.nih.gov/pubmed/30514331 http://dx.doi.org/10.1186/s13046-018-0954-5 |
Ejemplares similares
-
Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells
por: Brunelli, Laura, et al.
Publicado: (2014) -
Comparative metabolomics profiling of isogenic KRAS wild type and mutant NSCLC cells in vitro and in vivo
por: Brunelli, Laura, et al.
Publicado: (2016) -
Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS
por: Caiola, Elisa, et al.
Publicado: (2016) -
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
por: Caiola, Elisa, et al.
Publicado: (2018) -
Glutaminase Inhibition on NSCLC Depends on Extracellular Alanine Exploitation
por: Caiola, Elisa, et al.
Publicado: (2020)